Allogeneic CRISPR CAR-T Cell Therapy Hub Model
Underwrite universal donor TCR-knockout allogeneic CRISPR-edited CAR-T cell manufacturing cleanrooms (producing 5,000 patient infusion doses/year from single healthy donors). Model clinical off-take ($45,000/dose vs $400k autologous), and 20-yr IRR.
1. Capacity & Unit Economics
2. Financial Returns & Yield
UNIVERSAL OFF-THE-SHELF CAR-TAnnual Net EBITDA
$0 / yr
20-Yr Project IRR
0.0%
Gross Revenue
$0 / yr
Total CapEx
$0
Annual OpEx
$0 / yr